Elective cesarean delivery plus short-course lamivudine and zidovudine for the prevention of mother-to-child transmission of human immunodeficiency virus type 1

The purpose of this study was to evaluate the effect of elective cesarean delivery plus a lamivudine-zidovudine prophylaxis regimen on non-breastfeeding mothers with human immunodeficiency virus type 1 and their infants. Forty-six antiretroviral-naı̈ve, pregnant women with human immunodeficiency vir...

Full description

Saved in:
Bibliographic Details
Published in:American journal of obstetrics and gynecology 2004-03, Vol.190 (3), p.803-808
Main Authors: Panburana, Panyu, Sirinavin, Sayomporn, Phuapradit, Winit, Vibhagool, Asda, Chantratita, Wasun
Format: Article
Language:English
Subjects:
Adult
Anti-HIV Agents - therapeutic use
Biological and medical sciences
Cesarean delivery
Cesarean Section
Female
Gynecology. Andrology. Obstetrics
HIV Infections - epidemiology
HIV Infections - prevention & control
HIV Infections - transmission
HIV Infections - virology
HIV-1
Humans
Incidence
Infant, Newborn
Infant, Newborn, Diseases - epidemiology
Infectious Disease Transmission, Vertical - prevention & control
Lamivudine
Lamivudine - therapeutic use
Medical sciences
Perinatal prophylaxis
Pregnancy
Pregnancy Complications, Infectious
Treatment Outcome
Viral Load
Zidovudine
Zidovudine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The purpose of this study was to evaluate the effect of elective cesarean delivery plus a lamivudine-zidovudine prophylaxis regimen on non-breastfeeding mothers with human immunodeficiency virus type 1 and their infants. Forty-six antiretroviral-naı̈ve, pregnant women with human immunodeficiency virus type 1 were included. The prophylactic regimen was a lamivudine-zidovudine tablet (150 mg/300 mg) twice daily from week 34 of pregnancy until cesarean delivery at week 38 of gestation, preoperative intravenous zidovudine, and neonatal zidovudine syrup for 4 weeks. At weeks 34 and 38 of gestation, the median maternal viral loads were, respectively, 3.65 log 10 copies/mL (range, 2.34-4.70 log 10 copies/mL) and 2.51 log 10 copies/mL (range, 2.04-3.66 log 10 copies/mL; P
ISSN:0002-9378
1097-6868
DOI:10.1016/j.ajog.2003.09.034